Peptide Schedule
Gotratix5 residuesAEDRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Gotratix
Benefits
About Gotratix
Gotratix is a muscle-targeted peptide bioregulator in the Khavinson class, extracted from the striated muscle tissue of young calves through acid hydrolysis and ultrafiltration. Developed at the St. Petersburg Institute of Bioregulation and Gerontology, it contains a standardized mix of short-chain peptides (2-7 amino acid residues) with molecular weights below 10 kDa that are thought to selectively interact with myocyte gene promoter regions. The product is available in 200 mg oral capsules and doesn't require injection or reconstitution. According to the bioregulator model proposed by Vladimir Khavinson, these tissue-derived peptides can cross cell membranes and enter the nucleus, where they bind to specific DNA sequences in gene promoter regions. For muscle tissue, this is claimed to normalize protein synthesis within myocytes, restore cellular metabolism, and increase functional reserve capacity. Gotratix is marketed primarily for supporting muscle recovery, reducing fatigue during intense physical activity, and maintaining muscle function during aging. While the broader Khavinson bioregulator research program spans over 40 years and includes published studies on compounds like Cortexin and Epithalon, Gotratix itself lacks dedicated clinical trials in peer-reviewed international journals. The evidence supporting its muscle-specific claims comes mainly from the general bioregulator framework — the idea that organ-specific peptide extracts restore function in their tissue of origin — rather than controlled human studies of this particular product. Users should treat manufacturer claims with caution and understand that the regulatory status remains research-only outside of Russia and CIS countries.
Who Should Consider Gotratix
- Adults experiencing age-related muscle loss or sarcopenia
- Athletes seeking muscle recovery support between training sessions
- Individuals with occupational demands requiring sustained muscle performance
- Older adults looking to maintain muscle function and reduce fatigue
- Those interested in Khavinson bioregulator protocols for longevity
How Gotratix Works
Gotratix operates within the Khavinson bioregulator framework, where tissue-derived short peptides are proposed to act as epigenetic modulators of gene expression in their tissue of origin. The muscle-derived peptides in Gotratix are thought to cross myocyte cell membranes and enter the nucleus, where they interact with specific nucleotide sequences in gene promoter regions — a mechanism demonstrated in vitro for other short peptides in this class. These DNA-peptide interactions are believed to initiate transcription of genes involved in muscle protein synthesis, cellular repair, and metabolic regulation. Research on related Khavinson peptides has shown that short-chain peptides (2-7 amino acids) can modulate histone acetylation and DNA methylation patterns, affecting gene accessibility for transcription. For muscle tissue specifically, this is claimed to upregulate expression of structural proteins like myosin and actin, restore optimal metabolic enzyme activity, and normalize the balance between protein synthesis and degradation within myocytes. The peptides may also influence mitochondrial function in muscle cells, supporting energy production during contraction. However, these mechanisms are extrapolated from the broader bioregulator research platform rather than from Gotratix-specific studies.
What to Expect
No noticeable effects expected. The bioregulator peptides are beginning to interact with muscle cell gene expression pathways according to the proposed mechanism.
Some users anecdotally report reduced muscle fatigue and improved recovery between workouts, though placebo effects can't be ruled out given the lack of controlled trials.
Proposed peak period of the treatment course. Claimed improvements in muscle endurance, reduced soreness after physical activity, and better overall muscle tone.
Effects are said to persist after the course ends due to lasting gene expression changes. This claim is based on the broader bioregulator model rather than Gotratix-specific data.
Repeated courses are recommended for cumulative benefit. The manufacturer suggests that ongoing peptide supplementation maintains optimal myocyte peptide balance over time.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 200mg | Daily |
| Moderate | 400mg | 2x Daily |
| Aggressive | 400mg | 3x Daily |
Note: Gotratix (A-18) is a Khavinson-class peptide bioregulator derived from the triceps muscle tissue of young calves. It's supplied as oral capsules containing 200 mg of peptide complex per capsule. Standard courses run 1-2 months, repeated every 4-6 months. As a polypeptide complex rather than a single defined peptide, detailed pharmacokinetic data for individual components hasn't been published. No clinical trials have been registered on ClinicalTrials.gov, and the evidence base is limited to Khavinson's broader bioregulator research platform rather than Gotratix-specific studies.
How to Inject Gotratix
Gotratix is taken orally as capsules — no reconstitution or injection is needed. Take 1-2 capsules (200 mg each) one to two times daily, 15-20 minutes before meals. A standard course lasts 30 days. For maintenance, some protocols recommend 2 capsules once daily for 10 days, repeated every 3 months. If timing around training, take 30-45 minutes before a workout and again before the post-workout meal. Capsules should be swallowed whole with water. Do not exceed 4 capsules (800 mg) per day. Courses can be repeated after a 4-6 month break.
Cycling Protocol
Standard protocol: 1-2 capsules, 1-2 times daily for 30 days. Repeat every 4-6 months. An intensive loading phase of 2 capsules twice daily for 10 days followed by standard dosing for 20 days is used by some practitioners. Take 15-20 minutes before meals for best absorption.
Pharmacokinetics
Source: Estimated from short peptide complex kinetics; no Gotratix-specific pharmacokinetic studies published (extrapolated from Khavinson bioregulator class)
Loading the interactive decay curve.
Side Effects
Gotratix hasn't been associated with significant adverse effects in available reports. As with other Khavinson bioregulators, it's derived from animal tissue (young bovine muscle), so individuals with sensitivities to bovine proteins should exercise caution. Theoretical concerns about animal-derived peptide preparations include allergic reactions in predisposed individuals, though documented cases are rare across the broader bioregulator class. Mild gastrointestinal discomfort is occasionally reported with oral peptide supplements. The lack of formal pharmacovigilance data or published clinical trials means the side effect profile isn't well characterized by Western clinical standards.
Contraindications
- Pregnancy and breastfeeding (no safety data available)
- Known hypersensitivity to bovine-derived proteins or peptides
- Active autoimmune conditions affecting muscle tissue (myositis)
- Children under 18 (not studied in pediatric populations)
- Individuals with severe allergic history to animal-derived supplements
Drug Interactions
- No formal drug interaction studies have been published for Gotratix
- Theoretical interactions with immunosuppressive medications due to peptide bioactivity
- Use caution combining with other muscle-active peptides — additive or competing effects are possible
- No known interactions with common supplements or standard sports nutrition products
- Consult a healthcare provider if taking medications for neuromuscular conditions
Storage & Stability
Molecular Profile
Related Peptides
References
- Peptide Regulation of Gene Expression: A Systematic ReviewPubMed 34834147
- Short Peptides Regulate Gene ExpressionPubMed 27909961
- Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studiesPubMed 23734519
- Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies resultsPubMed 24003726
- Peptide bioregulation of aging: results and prospectsPubMed 19830585
- Peptide regulation of aging: 35-year research experiencePubMed 19902107